This technology is a composition containing suberic acid or its pharmaceutically acceptable salts as an active ingredient to prevent or treat muscle disorders such as muscle loss, atrophy, and degeneration. It can be formulated not only as a pharmaceutical product but also as a muscle-enhancing composition for health supplements, livestock feed, and cosmetics.
The aging population has led to an increase in patients with sarcopenia, which is associated with a higher risk of gait impairment, diabetes, and cardiovascular disease. However, there are currently no approved drugs specifically for treating sarcopenia, leaving patients reliant on limited options like drug repurposing.
This technology utilizes the dual action of suberic acid, which increases the activity of signaling proteins related to muscle protein synthesis while inhibiting the expression of muscle protein degradation enzymes, thereby inducing muscle differentiation, regeneration, and increased muscle mass. It can be applied to sarcopenia treatments, senior health supplements, and livestock feed, serving as a muscle health solution for both the aging population and the livestock industry.
US11096917B2, WO2018-128479A1